Pfizer receives FDA fast track designation for Duchenne muscular dystrophy investigational gene therapy

Pfizer

1 October 2020 - Pfizer today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy received fast track designation from the U.S. FDA. 

PF-06939926 is currently being evaluated to determine the safety and efficacy of this gene therapy in boys with Duchenne muscular dystrophy.

Read Pfizer press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Gene therapy , Fast track